The EPS miss reinforces the bearish sentiment for a pre-revenue biotech with no near-term catalysts until 2027 interim data. The $172.4M cash runway into H2 2028 provides a floor, but without a partnership or data catalyst, the stock is likely to drift lower. Monitor for any partnership or financing announcements given the $76M market cap.
PLRX drugs
PLRX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $1.18entry
- T+1 · 6mo ago 0.00%α −0.54% · $1.18
- T+5 · 6mo ago 0.00%α −0.08% · $1.18
- T+20 · 5mo ago −1.69%α +0.03% · $1.16
- T+60 · 3mo ago −11.02%α −15.40% · $1.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue biotech). Net loss narrowed to $20.0M from $56.2M a year ago due to lower R&D spend after terminating bexotegrast. The company highlighted early clinical progress for PLN-101095 in ICI-refractory tumors, including a complete response and two partial responses, but the EPS miss and absence of near-term catalysts cap the upside for a $76M market cap stock.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.38 missed consensus of -$0.36 (-6.2% miss)
- Revenue was $0 (pre-revenue clinical-stage biotech)
- Net loss narrowed to $20.0M from $56.2M YoY, driven by lower R&D spend after bexotegrast termination
- Cash, cash equivalents and short-term investments of $172.4M expected to fund operations into H2 2028
- First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027
- Updated Phase 1 data at AACR showed 1 complete response, 2 partial responses in ICI-refractory tumors
Financial Impact
EPS miss of $0.02 per share vs consensus; net loss of $20.0M vs $56.2M YoY
Risk Factors
- Clinical trial failure or delay for PLN-101095
- Cash burn rate may accelerate if trials expand
- No revenue and reliance on equity or debt financing
- Competition from other checkpoint resistance therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292302 |
Track record
8 reports on PLRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
- Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Viewing Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
- Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
- Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
- Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
- Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers